Bradley Wilson, MD
Urology · Norman, OKNPI 1407084791
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 56.3% of the total. 2025 is the largest year on record at $4,900, 3.9 times the $1,252 reported in 2019.
Across 235 payments — averaging $44.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Neotract Inc.$866
- Astellas Pharma US Inc$597
- Coloplast$551
- Boston Scientific$541
- Axonics, Inc.$351
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$4,00038%
- Travel & lodging$2542%
- Food & beverage$5,93257%
- Education$2182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 73 | $5,854 |
| Neotract Inc. | 9 | $866 |
| Astellas Pharma US Inc | 38 | $597 |
| Coloplast | 19 | $551 |
| Boston Scientific | 22 | $541 |
| Axonics, Inc. | 9 | $351 |
| Teleflex LLC | 8 | $308 |
| Healthtronics Stone Solutions, LLC | 2 | $226 |
| Pfizer | 10 | $204 |
| Johnson & Johnson(2 entities) | 6 | $138 |
| Caldera Medical, Inc | 4 | $97 |
| AbbVie(2 entities) | 5 | $85 |
| Accord Healthcare, Inc. | 4 | $69 |
| Endo Pharmaceuticals Inc. | 4 | $64 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Procept Biorobotics Corporation | 2 | $44 |
| Bayer | 2 | $36 |
| Urocure LLC | 1 | $36 |
| AstraZeneca | 1 | $35 |
| Civco Medical Instruments | 1 | $33 |
| Laborie Medical Technologies Corp. | 2 | $32 |
| Tolmar Pharmaceuticals, Inc. | 2 | $30 |
| Merck | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Urovant Sciences Inc | 1 | $18 |
| Hollister Incorporated | 1 | $15 |
| Amgen | 1 | $15 |
| Blue Earth Diagnostics | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$4,650
- UroLift$630
- Mobile Cryoblation Services$205
- AMS 700 CXR RTE KIT$125
- Bulkamid$105
- Axonics$105
How this compares
$10,405 in reported general payments places this provider in the 80th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 27 | $371,419 |
| MyrbetriqMirabegron | 209 | $203,411 |
| GemtesaVibegron | 137 | $106,043 |
| OrgovyxRelugolix | 34 | $90,910 |
| ElmironPentosan Polysulfate Sodium | 17 | $20,652 |
| Tamsulosin Hcl | 796 | $13,664 |
| Mirabegron ErMirabegron | 11 | $10,013 |
| NitrofurantoinNitrofurantoin Macrocrystal | 196 | $7,939 |
| Methenamine Hippurate | 122 | $7,696 |
| Trospium Chloride ErTrospium Chloride | 28 | $6,456 |
| Estradiol | 108 | $6,446 |
| Finasteride | 325 | $5,962 |
| Tolterodine Tartrate ErTolterodine Tartrate | 90 | $5,759 |
| Trospium Chloride | 71 | $5,331 |
| Darifenacin ErDarifenacin Hydrobromide | 16 | $5,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $597 | $574,830236 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $55 | $196,952171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 urology providers in Oklahoma.
Other urology in Norman
- Samuel DakilNorman$6K
- Mohammad RamadanOklahoma City$207K
- Michael CooksonOklahoma City$132K
- Melanie KetchandjiTulsa$111K
- Kelly StrattonOklahoma City$62K
- Ashley BowenOklahoma City$32K
- Marc MilstenTulsa$29K
- Scott LitwillerTulsa$27K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Charles PritchardTulsa$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.